---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060028"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:51:14.753865+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports Q1 net loss $12.3M ($0.02/sh); cash $180.6M after $177M raise

## Summary
- Net loss $12.3M for Q1 2024 vs $0.4M year ago; R&D expense rose 127% to $7.5M.
- Cash, equivalents & short-term investments $180.6M at March 31 vs $9.2M at Dec 31; additional $49.5M raised via ATM in April.
- Raised $177.2M gross from public/private offerings including $20.8M private placement and Lantheus investment.
- Phase 1/2a for [212Pb]VMT-α-NET dosed 9 patients; combo trial with Bristol Myers' nivolumab for VMT01 in melanoma planned.
- Disclosed new pre-IND asset PSV359 targeting FAP-α; IND expected late 2024; brachytherapy divested to GT Medical.

## SEC filing metadata
- accession: 0000950170-24-060028
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017024060028/0000950170-24-060028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017024060028/catx-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060028
- JSON: https://secwatch.observer/filing/0000950170-24-060028.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060028.txt

## Key facts
- Earnings Releases
  Perspective Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 15, 2024, Perspective Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000095017024060028/0000950170-24-060028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.